Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) entered a new phase in its corporate life this month: from clinical-stage story stock to a company with an FDA-approved, commercially launchable cardiovascular product. The catalyst is CARDAMYST™ (etripamil) nasal spray, now approved in the